ProTrials Research teams up with Calithera for early trial help

Californian CRO ProTrials Research has been picked by fellow CA-based cancer biotech Calithera Biosciences ($CALA) to help it run an early-stage trial for its oncology candidate.

Under the deal, financial terms of which were not shared, ProTrials will deliver clinical trial development support for Calithera’s first-in-class inhibitor CB-839 program, which targets glutaminase, an enzyme found in tumor metabolism.

The candidate is currently in Phase I testing with a focus on certain types of breast and kidney cancers.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“We are extremely pleased that Calithera has selected ProTrials to support research into CB-839,” said Jodi Andrews, co-founder and co-CEO of ProTrials.

“We recognize the potential of CB-839 to become an important therapeutic agent for the treatment of cancer, and look forward to applying our expertise to support Calithera's development of this first-in-class investigational compound.”

ProTrials works across a number of therapy areas and through Phases I-IV, and notes among its successfully finished trials a Phase III study for an AIDS vaccine; a potential small molecule drug for prostate cancer; and an oral medication for Alzheimer’s disease.

Calithera meanwhile just yesterday announced that the FDA has accepted its IND app for its investigational drug CB-1158 for the treatment of solid tumors. CB-1158, also a first-in-class drug, works as an orally available small molecule inhibitor of the enzyme arginase. 

- check out the release

Read more on

Suggested Articles

U.S.-China biotech Brii Biosciences is pushing out into new territory with a new hire alongside a focus on a new R&D area.

John Ratliff’s position has changed three times this fall, but now, much like the falling leaves, he looks to have settled.

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.